First Tracks director granted options and RSUs

First Tracks Biotherapeutics director Ware J. Anthony reported new equity compensation awards.

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Ware J. Anthony reported new equity compensation awards. On May 12, 2026, he received stock options covering 7,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest in equal monthly installments, with 1/12 of the total vesting each month starting June 12, 2026, as long as he continues serving the company.

He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest 100% on the date of First Tracks’ 2027 annual meeting of shareholders, subject to his continued service.

Insider Trade Summary

Grant/Award: 9,500 shares

Grant/Award 2 txns

Insider Ware J. Anthony

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,500	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	7,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 2,500 contracts (Direct); Stock Option (right to buy) — 7,000 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. F2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Stock options granted: 7,000 options Option exercise price: $17.81 per share Option expiration: May 11, 2036 +3 more

6 metrics

Stock options granted 7,000 options Grant to director on May 12, 2026

Option exercise price $17.81 per share Stock option grant to director

Option expiration May 11, 2036 End of option term

RSUs granted 2,500 RSUs Equity award to director on May 12, 2026

RSU vesting date 2027 annual meeting 100% of RSUs vest at 2027 shareholder meeting

Option vesting start June 12, 2026 1/12 of options vest monthly from this date

Key Terms

Restricted Stock Unit, RSU, stock option, vests, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

stock option financial

"The stock option vests as to 1/12 of the total shares monthly"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vests financial

"The RSUs vests as to 100% of the total RSUs on the date"

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did First Tracks Biotherapeutics (TRAX) report in this Form 4/A?

The filing shows director Ware J. Anthony received equity compensation. He was granted stock options for 7,000 shares at a $17.81 exercise price and 2,500 restricted stock units, all tied to continued service with First Tracks Biotherapeutics.

How many stock options did TRAX director Ware J. Anthony receive and on what terms?

Ware J. Anthony received options on 7,000 shares of First Tracks common stock. The options have a $17.81 exercise price, expire on May 11, 2036, and vest in 12 equal monthly installments starting June 12, 2026, contingent on continued service.

What restricted stock unit (RSU) award did TRAX disclose for its director?

The filing reports a grant of 2,500 restricted stock units to director Ware J. Anthony. Each RSU equals one share of common stock for no cash consideration and will vest in full at the company’s 2027 annual meeting of shareholders, subject to his continued service.

Are the TRAX director’s reported transactions open-market share purchases or sales?

The transactions are equity compensation awards, not open-market trades. They consist of a stock option grant and an RSU grant made at no cash cost to the director, subject to vesting conditions based on his ongoing service with First Tracks Biotherapeutics.

When do Ware J. Anthony’s TRAX equity awards start and finish vesting?

The stock options start vesting June 12, 2026, with 1/12 of the 7,000 options vesting monthly until fully vested. The 2,500 RSUs vest 100% on the date of First Tracks Biotherapeutics’ 2027 annual meeting of shareholders, assuming he continues to serve the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ware J. Anthony

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	05/12/2026		A		2,500		(2)	(2)	Common Stock	2,500	$0	2,500	D
Stock Option (right to buy)	$17.81	05/12/2026		A		7,000		(3)	05/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

This amended Form 4, as originally filed on May 14, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 7,000 stock options and 2,500 RSUs originally granted to the Reporting Person on May 12, 2026.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)